May
2020
ERC receives a positive Opinion to commence a paediatric investigation plan(clinical trial) from the European Medicines Agency for treatment of children between 3 and 18 years of age with relapsing malignant glioma with its product Gliovac/ERC1671.
Apr
2020
In Q2 2020 after enrolling about 40 patients in the Phase II clinical trial, ERC will submit its request for commercialization in the USA.
Apr
2020
Filing of a patent against virus SARS-CoV-2 (COVID-19 coronavirus) for a vaccine called COVIDVAC.
Apr
2020
Dana Farber (Harvard) is expected to enter as the second site starting its contribution to the Phase II clinical trial.
Apr
2020
ERC Worldwide today announced the launch of the Company’s development program for its therapeutic and prophylactic vaccine against the new coronavirus SARS-CoV-2.   The technology is based on ERC’s Gliovac/ERC1671 glioblastoma vaccine platform currently in an FDA approved clinical trial in the US.
Feb
2020
Thanks to the optimization of Gliovac, exceptional results to date.
Jan
2020
Introduction of the commercialization request to UK.
Sep
2019
Single Technical Appraisal of ERC1671 for treating recurrent glioma by NICE (UK).
Jun
2019
Patients expressed interest for “Right to try” and the first vaccines were administered.
Oct
2018
 “Right to try”. Gliovac can be prescribed and invoiced in Southern California, USA.
Mar
2017
 Preparation of the commercialization request at the FDA for Gliovac.
Dec
2016
GMP certification of the production site in the Netherlands.
Jun
2016
Agreement with USC (University of Southern California) for a future set-up of an immunotherapy centre.
Mar
2016
 Support of Dana Farber / Harvard to ERC’s approach and agreement for later participation in the Phase II.
Jan
2016
Projects : International studies
Submission of a phase II in EU   -  first line for patient unresponding to TMZ.
Submission of a phase I in Australia -  first line  combined with RT.
 
Jan
2015
« Seal of excellence » in project development from European Commission. 
Jan
2014
ERC own GMP facilities (the Netherlands) and tissue bank.
Acquisition of the patent:   PCT/US11/57654
Vaccine, Therapeutic Composition and Methods for Treating or Inhibiting Glioblastoma 
Jan
2013
Phase II FDA Approval in recurrent patients - recruiting.
Orphan Drug Status granted by EMA.                               
Nov
2012
Submission of application for EMA orphan drug designation.
Compassionate use in Canada considered by approval authorities. (Health Canada)
Confirmation for NID protocol meeting (FDA) schedule on January 9th, 2013.
Sep
2012
First patient reaching total remission.
May
2012
Single patient INDs 15022 and 15087 granted by US FDA.
Mar
2012
Second patient vaccinated in Belgium also for compassionate use.
Jan
2012
The company has designed and initiated a 15 month pre-clinical development plan which will allow it to apply for a Phase I/II clinical trial in glioblastoma patients.
First vaccination of patients under compassionate use.
Jan
2011
The company obtained Orphan Drug status for Gliovac/ERC1671 from the US FDA.
The company obtained the status SME from the EMA which offers significant advantages in terms of fee waivers for EMA guidance and assessments of marketing authorization applications.
The company has put into place a scientific team with experience in cell culture and set up two scientific advisory boards, one in Europe and one in the United States.
Oct
2010
Published article on the successful and statistically significant preclinical animal tests (conducted in rats having two strains of malignant gliomas); e.g. Anit-cancer Agents in Medicinal Chemistry, 2010, Vol. 10, No. 6; Hofman et al.
Oct
2009
The company obtained Advanced Medical Therapy Product status for Gliovac/ERC1671 from the EMA. (classification: somatic cell therapy)
Jul
2009
Erc settled in its main office in Isnes. (Belgium)
Implementation of a "cleanroom" at the Hospital of South of Luxembourg in Arlon (Belgium) with the set-up of tissue bank, whereby the clinical trials of the company can be compliant with EU standards.
Feb
2008
Creation of ERC.
Jan
2007
Patent.  PCT/EP2007/050807 (WO/2007/085648)
Tumor Vaccine Comprising Allogeneic or Xenogeneic tumor cells.
Jan
2006
Proof-of-Concept
Stathopoulos, A., C et al. (2008) Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens proof of principle in two strains of rat.